OpSCF
Latest Information Update: 28 Jun 2025
At a glance
- Originator Opsidio
- Class Anti-inflammatories; Antifibrotics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Stem cell factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Atopic dermatitis
- No development reported Fibrosis; Inflammation
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for preclinical development in Fibrosis in USA (SC)
- 28 Jun 2025 No recent reports of development identified for preclinical development in Inflammation in USA (SC, Injection)
- 29 Nov 2023 Opsidio initiates a phase Ia/b trial (In volunteers) prior to November 2023